FI102075B1 - Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit - Google Patents

Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit

Info

Publication number
FI102075B1
FI102075B1 FI873141A FI873141A FI102075B1 FI 102075 B1 FI102075 B1 FI 102075B1 FI 873141 A FI873141 A FI 873141A FI 873141 A FI873141 A FI 873141A FI 102075 B1 FI102075 B1 FI 102075B1
Authority
FI
Finland
Prior art keywords
glycosylated
vectors
nucleic acid
recombinant nucleic
preparing
Prior art date
Application number
FI873141A
Other languages
English (en)
Swedish (sv)
Other versions
FI102075B (fi
FI873141A0 (fi
FI873141A (fi
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Publication of FI873141A0 publication Critical patent/FI873141A0/fi
Publication of FI873141A publication Critical patent/FI873141A/fi
Application granted granted Critical
Publication of FI102075B publication Critical patent/FI102075B/fi
Publication of FI102075B1 publication Critical patent/FI102075B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Auxiliary Devices For Music (AREA)
  • Fertilizers (AREA)
FI873141A 1985-11-19 1987-07-16 Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit FI102075B1 (fi)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US79966985A 1985-11-19 1985-11-19
US79966885A 1985-11-19 1985-11-19
US79966985 1985-11-19
US79966885 1985-11-19
US84395886 1986-03-25
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US88155386 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4
US90821586 1986-09-17
PCT/US1986/002464 WO1987002990A1 (en) 1985-11-19 1986-11-19 Mammalian interleukin-4
US8602464 1986-11-19

Publications (4)

Publication Number Publication Date
FI873141A0 FI873141A0 (fi) 1987-07-16
FI873141A FI873141A (fi) 1987-07-16
FI102075B FI102075B (fi) 1998-10-15
FI102075B1 true FI102075B1 (fi) 1998-10-15

Family

ID=27542219

Family Applications (1)

Application Number Title Priority Date Filing Date
FI873141A FI102075B1 (fi) 1985-11-19 1987-07-16 Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit

Country Status (23)

Country Link
EP (3) EP0230107A1 (fi)
JP (2) JP2557361B2 (fi)
KR (1) KR940007773B1 (fi)
CN (1) CN1020472C (fi)
AT (2) ATE140009T1 (fi)
AU (1) AU610057B2 (fi)
CZ (1) CZ414191A3 (fi)
DE (2) DE3650538T2 (fi)
DK (1) DK371087A (fi)
ES (2) ES2153444T3 (fi)
FI (1) FI102075B1 (fi)
GR (1) GR3021198T3 (fi)
HK (2) HK1005594A1 (fi)
HU (1) HU208710B (fi)
IE (1) IE80828B1 (fi)
IL (1) IL80678A (fi)
MY (1) MY101972A (fi)
NO (1) NO301234B1 (fi)
NZ (1) NZ218332A (fi)
OA (1) OA08947A (fi)
PT (1) PT83761B (fi)
SK (1) SK414191A3 (fi)
WO (1) WO1987002990A1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (ja) * 1985-09-30 1995-05-10 佑 本庶 新規なポリペプチドをコードするｄｎａ及びその製造方法
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
AU620537B2 (en) * 1986-12-19 1992-02-20 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
AU2257488A (en) * 1987-07-29 1989-03-01 Schering Biotech Corporation Purification of human interleukin-4 expressed in escherichia coli
DE3882611T2 (de) * 1987-08-03 1993-12-23 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
DE68908431T2 (de) * 1988-02-02 1993-12-23 Schering Biotech Corp Methode zur Verminderung der Immunglobulin-E-Reaktion.
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
EP0370090B1 (en) * 1988-05-13 1996-07-10 University Patents, Inc. Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU4947090A (en) * 1988-12-21 1990-07-10 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
EP0454736A4 (en) * 1989-01-20 1993-05-12 The University Of Melbourne Fibrinolysis
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
EP0502080A4 (en) * 1989-11-21 1993-02-10 The University Of Melbourne Anti-inflammatory compositions and methods
SE465039B (sv) * 1989-11-23 1991-07-15 Chemrec Ab Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
ZA9010190B (en) * 1989-12-20 1991-08-28 Schering Corp Antibody antagonists of human interleukin-4
ATE133074T1 (de) * 1990-03-21 1996-02-15 Schering Corp Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
IL100402A0 (en) * 1990-12-19 1992-09-06 Schering Corp Use of il-4 to enhance immune response to immunogens in vaccines
ES2085003T3 (es) * 1991-01-10 1996-05-16 Schering Corp Uso de il-4 para mejorar la fase reparadora de la curacion y restaño de heridas y para mejorar la curacion de heridas infectadas y las heridas de mamiferos diabeticos.
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
WO1999058947A2 (en) * 1998-05-12 1999-11-18 Isis Pharmaceuticals, Inc. Modulation of molecular interaction sites on rna and other biomolecules
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
CN102212888A (zh) * 2011-03-17 2011-10-12 靳海峰 一种基于高通量测序的免疫组库构建方法
US11400134B2 (en) 2015-10-09 2022-08-02 Bioniz, Llc Modulating gamma-c-cytokine activity
CN113874075A (zh) 2019-05-03 2021-12-31 比奥尼斯有限责任公司 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
AU7082487A (en) * 1986-02-11 1987-08-25 University Of Texas System, The Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
AU620537B2 (en) * 1986-12-19 1992-02-20 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
DK371087A (da) 1987-09-21
HUT43630A (en) 1987-11-30
JP2557361B2 (ja) 1996-11-27
GR3021198T3 (en) 1996-12-31
HK1008823A1 (en) 1999-05-21
EP0249613B1 (en) 1996-07-03
JPH0884591A (ja) 1996-04-02
PT83761A (en) 1986-12-01
IL80678A0 (en) 1987-02-27
AU610057B2 (en) 1991-05-16
CN86108579A (zh) 1988-01-27
MY101972A (en) 1992-02-29
EP0675136A3 (en) 1996-03-13
JP2568394B2 (ja) 1997-01-08
DE3650538D1 (de) 1996-08-08
DE3650751D1 (de) 2001-02-22
WO1987002990A1 (en) 1987-05-21
FI102075B (fi) 1998-10-15
CN1020472C (zh) 1993-05-05
PT83761B (pt) 1989-06-30
ATE140009T1 (de) 1996-07-15
ES2088858T3 (es) 1996-10-01
OA08947A (en) 1990-11-30
NZ218332A (en) 1993-04-28
IE80828B1 (en) 1999-03-10
NO301234B1 (no) 1997-09-29
NO872988L (no) 1987-09-18
SK414191A3 (en) 1995-07-11
IL80678A (en) 1999-05-09
EP0230107A1 (en) 1987-07-29
CZ414191A3 (en) 1993-04-14
FI873141A0 (fi) 1987-07-16
DK371087D0 (da) 1987-07-16
DE3650538T2 (de) 1996-12-12
KR940007773B1 (ko) 1994-08-25
ATE198754T1 (de) 2001-02-15
IE863042L (en) 1987-05-19
JPS63501401A (ja) 1988-06-02
AU6733487A (en) 1987-06-02
FI873141A (fi) 1987-07-16
EP0675136A2 (en) 1995-10-04
HU208710B (en) 1993-12-28
ES2153444T3 (es) 2001-03-01
NO872988D0 (no) 1987-07-17
EP0675136B1 (en) 2001-01-17
DE3650751T2 (de) 2001-08-02
EP0249613A1 (en) 1987-12-23
HK1005594A1 (en) 1999-01-15

Similar Documents

Publication Publication Date Title
FI102075B1 (fi) Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit
KR870700099A (ko) 에리트로 포이에틴의 제조방법
ATE49233T1 (de) Vektoren zur transformation von hefe.
FI20000025A (fi) Menetelmä hemoglobiinin kaltainen yhdistelmäproteiinin valmistamiseksi
EP0092182A3 (en) Preparation of functional human urokinase proteins
ES548421A0 (es) Un procedimiento para la obtencion de un anticuerpo monoclo-nal
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
ATE110112T1 (de) Verfahren und systeme zur herstellung von hiv- antigenen.

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: SCHERING BIOTECH CORPORATION